ADA 2021: Novo trumpets higher-dose Ozempic data as Lilly competitors loom
Novo Nordisk’s semaglutide franchise has taken off in a big way. Type 2 diabetes med Ozempic smashed the blockbuster barrier in 2019, the same year the company launched its oral option, Rybelsus. Now, the Danish diabetes major is touting data on a higher-dose prospect. In a late-stage trial, Ozempic 2 mg trumped its 1-mg predecessor on blood… Read More »